Does the media prefer LMAT or CLPT?

In the previous week, LeMaitre Vascular had 8 more articles in the media than ClearPoint Neuro. MarketBeat recorded 11 mentions for LeMaitre Vascular and 3 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.34 beat LeMaitre Vascular's score of 1.17 indicating that ClearPoint Neuro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CLPT or INSP?

In the previous week, Inspire Medical Systems had 6 more articles in the media than ClearPoint Neuro. MarketBeat recorded 9 mentions for Inspire Medical Systems and 3 mentions for ClearPoint Neuro. Inspire Medical Systems' average media sentiment score of 1.69 beat ClearPoint Neuro's score of 1.34 indicating that Inspire Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inspire Medical Systems 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to CLPT or KMTS?

In the previous week, ClearPoint Neuro and ClearPoint Neuro both had 3 articles in the media. ClearPoint Neuro's average media sentiment score of 1.34 beat Kestra Medical Technologies' score of 0.62 indicating that ClearPoint Neuro is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kestra Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OMCL or CLPT?

In the previous week, Omnicell had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 7 mentions for Omnicell and 3 mentions for ClearPoint Neuro. Omnicell's average media sentiment score of 1.45 beat ClearPoint Neuro's score of 1.34 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, CLPT or CNMD?

CONMED has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ClearPoint Neuro $36.97M 12.83 -$25.54M -$1.18 N/A CONMED $1.37B 1.09 $47.06M $1.85 26.98

Does the media refer more to CLPT or CNMD?

In the previous week, CONMED had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 5 mentions for CONMED and 3 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.34 beat CONMED's score of 0.95 indicating that ClearPoint Neuro is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CONMED 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

ClearPoint Neuro (CLPT) Competitors

$15.55 -0.39 (-2.45%)

As of 08/28/2026 04:00 PM Eastern

Compare

CLPT vs. LMAT, INSP, KMTS, OMCL, and CNMD

Should you buy ClearPoint Neuro stock or one of its competitors? ClearPoint Neuro's main competitors and comparable companies include LeMaitre Vascular (LMAT), Inspire Medical Systems (INSP), Kestra Medical Technologies (KMTS), Omnicell (OMCL), and CONMED (CNMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does ClearPoint Neuro compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

LeMaitre Vascular has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LeMaitre Vascular has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	7.37	$57.73M	$2.85	28.23
ClearPoint Neuro	$36.97M	12.83	-$25.54M	-$1.18	N/A

LeMaitre Vascular has a net margin of 25.02% compared to ClearPoint Neuro's net margin of -81.76%. LeMaitre Vascular's return on equity of 15.63% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	25.02%	15.63%	10.06%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

LeMaitre Vascular currently has a consensus target price of $110.60, indicating a potential upside of 37.48%. ClearPoint Neuro has a consensus target price of $25.67, indicating a potential upside of 65.06%. Given ClearPoint Neuro's higher probable upside, analysts plainly believe ClearPoint Neuro is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, LeMaitre Vascular had 8 more articles in the media than ClearPoint Neuro. MarketBeat recorded 11 mentions for LeMaitre Vascular and 3 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.34 beat LeMaitre Vascular's score of 1.17 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LeMaitre Vascular beats ClearPoint Neuro on 11 of the 15 factors compared between the two stocks.

How does ClearPoint Neuro compare to Inspire Medical Systems?

ClearPoint Neuro (NASDAQ:CLPT) and Inspire Medical Systems (NYSE:INSP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 2.2% of Inspire Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Inspire Medical Systems has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.83	-$25.54M	-$1.18	N/A
Inspire Medical Systems	$911.98M	1.95	$145.42M	$4.62	13.31

In the previous week, Inspire Medical Systems had 6 more articles in the media than ClearPoint Neuro. MarketBeat recorded 9 mentions for Inspire Medical Systems and 3 mentions for ClearPoint Neuro. Inspire Medical Systems' average media sentiment score of 1.69 beat ClearPoint Neuro's score of 1.34 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inspire Medical Systems	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ClearPoint Neuro has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

ClearPoint Neuro currently has a consensus price target of $25.67, indicating a potential upside of 65.06%. Inspire Medical Systems has a consensus price target of $66.19, indicating a potential upside of 7.64%. Given ClearPoint Neuro's stronger consensus rating and higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21

Inspire Medical Systems has a net margin of 15.03% compared to ClearPoint Neuro's net margin of -81.76%. Inspire Medical Systems' return on equity of 8.64% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
Inspire Medical Systems	15.03%	8.64%	7.45%

Summary

Inspire Medical Systems beats ClearPoint Neuro on 12 of the 17 factors compared between the two stocks.

How does ClearPoint Neuro compare to Kestra Medical Technologies?

ClearPoint Neuro (NASDAQ:CLPT) and Kestra Medical Technologies (NASDAQ:KMTS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

ClearPoint Neuro has a net margin of -81.76% compared to Kestra Medical Technologies' net margin of -138.35%. Kestra Medical Technologies' return on equity of -57.38% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
Kestra Medical Technologies	-138.35%	-57.38%	-41.10%

ClearPoint Neuro has higher earnings, but lower revenue than Kestra Medical Technologies. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.83	-$25.54M	-$1.18	N/A
Kestra Medical Technologies	$95.13M	15.79	-$131.61M	-$2.42	N/A

In the previous week, ClearPoint Neuro and ClearPoint Neuro both had 3 articles in the media. ClearPoint Neuro's average media sentiment score of 1.34 beat Kestra Medical Technologies' score of 0.62 indicating that ClearPoint Neuro is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kestra Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ClearPoint Neuro presently has a consensus target price of $25.67, indicating a potential upside of 65.06%. Kestra Medical Technologies has a consensus target price of $28.14, indicating a potential upside of 9.76%. Given ClearPoint Neuro's higher possible upside, equities analysts plainly believe ClearPoint Neuro is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

30.1% of ClearPoint Neuro shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by insiders. Comparatively, 5.3% of Kestra Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ClearPoint Neuro has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Summary

ClearPoint Neuro beats Kestra Medical Technologies on 9 of the 15 factors compared between the two stocks.

How does ClearPoint Neuro compare to Omnicell?

Omnicell (NASDAQ:OMCL) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

In the previous week, Omnicell had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 7 mentions for Omnicell and 3 mentions for ClearPoint Neuro. Omnicell's average media sentiment score of 1.45 beat ClearPoint Neuro's score of 1.34 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.7% of Omnicell shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Omnicell has a net margin of 3.13% compared to ClearPoint Neuro's net margin of -81.76%. Omnicell's return on equity of 5.66% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

Omnicell presently has a consensus price target of $57.86, indicating a potential upside of 74.90%. ClearPoint Neuro has a consensus price target of $25.67, indicating a potential upside of 65.06%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts plainly believe Omnicell is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Omnicell has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.27	$2.05M	$0.84	39.38
ClearPoint Neuro	$36.97M	12.83	-$25.54M	-$1.18	N/A

Omnicell has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Summary

Omnicell beats ClearPoint Neuro on 13 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to CONMED?

ClearPoint Neuro (NASDAQ:CLPT) and CONMED (NYSE:CNMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

CONMED has a net margin of 4.12% compared to ClearPoint Neuro's net margin of -81.76%. CONMED's return on equity of 14.31% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
CONMED	4.12%	14.31%	6.33%

ClearPoint Neuro presently has a consensus price target of $25.67, indicating a potential upside of 65.06%. CONMED has a consensus price target of $41.40, indicating a potential downside of 17.07%. Given ClearPoint Neuro's stronger consensus rating and higher possible upside, equities analysts clearly believe ClearPoint Neuro is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CONMED	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

ClearPoint Neuro has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, CONMED has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

In the previous week, CONMED had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 5 mentions for CONMED and 3 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.34 beat CONMED's score of 0.95 indicating that ClearPoint Neuro is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CONMED	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

30.1% of ClearPoint Neuro shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 0.3% of CONMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CONMED has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.83	-$25.54M	-$1.18	N/A
CONMED	$1.37B	1.09	$47.06M	$1.85	26.98

Summary

ClearPoint Neuro and CONMED tied by winning 8 of the 16 factors compared between the two stocks.

Get ClearPoint Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLPT vs. The Competition

Export

Metric	ClearPoint Neuro	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$474.34M	$5.88B	$7.21B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	-13.18	25.92	273.16	25.42
Price / Sales	12.83	68.66	630.81	94.42
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	15.71	6.18	11.08	6.36
Net Income	-$25.54M	$149.94M	$3.48B	$349.79M
7 Day Performance	1.04%	-0.24%	0.13%	-0.80%
1 Month Performance	6.65%	6.18%	7.08%	4.13%
1 Year Performance	48.24%	6.30%	24.67%	15.17%

ClearPoint Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLPT ClearPoint Neuro	2.3658 of 5 stars	$15.55 -2.4%	$25.67 +65.1%	+48.2%	$474.34M	$36.97M	N/A	110	Positive News
LMAT LeMaitre Vascular	4.8475 of 5 stars	$80.31 +0.4%	$110.60 +37.7%	-15.6%	$1.84B	$262.43M	28.20	490	Positive News
INSP Inspire Medical Systems	3.4067 of 5 stars	$61.49 +0.0%	$66.19 +7.6%	-34.5%	$1.78B	$911.98M	13.31	1,333	Positive News
KMTS Kestra Medical Technologies	1.7943 of 5 stars	$27.22 +0.8%	$28.14 +3.4%	+58.9%	$1.60B	$95.13M	N/A	300
OMCL Omnicell	4.3 of 5 stars	$34.33 -1.0%	$57.86 +68.5%	+1.5%	$1.56B	$1.25B	40.87	3,580	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLPT) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Competitors

CLPT vs. LMAT, INSP, KMTS, OMCL, and CNMD

How does ClearPoint Neuro compare to LeMaitre Vascular?

Summary

How does ClearPoint Neuro compare to Inspire Medical Systems?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Summary

How does ClearPoint Neuro compare to Omnicell?

Summary

How does ClearPoint Neuro compare to CONMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Competitors

CLPT vs. LMAT, INSP, KMTS, OMCL, and CNMD

How does ClearPoint Neuro compare to LeMaitre Vascular?

Which has more risk & volatility, LMAT or CLPT?

Do insiders & institutionals have more ownership in LMAT or CLPT?

Which has better valuation & earnings, LMAT or CLPT?

Is LMAT or CLPT more profitable?

Do analysts rate LMAT or CLPT?

Does the media prefer LMAT or CLPT?

Summary

How does ClearPoint Neuro compare to Inspire Medical Systems?

Do insiders and institutionals believe in CLPT or INSP?

Which has stronger valuation & earnings, CLPT or INSP?

Does the media refer more to CLPT or INSP?

Which has more volatility & risk, CLPT or INSP?

Do analysts rate CLPT or INSP?

Is CLPT or INSP more profitable?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Is CLPT or KMTS more profitable?

Which has better valuation and earnings, CLPT or KMTS?

Does the media refer more to CLPT or KMTS?

Do analysts rate CLPT or KMTS?

Do insiders & institutionals believe in CLPT or KMTS?

Which has more volatility and risk, CLPT or KMTS?

Summary

How does ClearPoint Neuro compare to Omnicell?

Does the media prefer OMCL or CLPT?

Do institutionals and insiders believe in OMCL or CLPT?

Is OMCL or CLPT more profitable?

Do analysts prefer OMCL or CLPT?

Which has preferable earnings and valuation, OMCL or CLPT?

Which has more risk and volatility, OMCL or CLPT?

Summary

How does ClearPoint Neuro compare to CONMED?

Is CLPT or CNMD more profitable?

Do analysts prefer CLPT or CNMD?

Which has more risk & volatility, CLPT or CNMD?

Does the media refer more to CLPT or CNMD?

Do institutionals & insiders believe in CLPT or CNMD?

Which has preferable earnings and valuation, CLPT or CNMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools